FX.co ★ SAB Biotherapeutics' Executive Chairman Reich Takes On Addl. Role As CEO

On Friday, SAB Biotherapeutics, Inc. (SABS) revealed that its current Executive Chairman, Samuel Reich, will assume the added position of Chief Executive Officer effective immediately.

Reich's association with SAB began in 2021 when he assumed the role of Executive Chairman after the merger with Big Cypress Acquisition Group. Before this, he had occupied several senior leadership roles at Big Cypress, including those of Chief Executive Officer and Chief Financial Officer.